The celebrity multiplier effect
A nutritionist with a social media following launches a gut health supplement company. Twelve months later, she's secured multi-million pound backing from the same venture firm that invested in Soho House and LEON. Welcome to 2024, where the path from Instagram to institutional capital has never been shorter—or more revealing about what investors actually value.
Epetōme, founded by Emily English in 2023, has closed a funding round led by Active Partners and Redrice Ventures just over a year after launch. The company hasn't disclosed the exact figure, but both investors bring serious pedigree. Active Partners has backed Honest Burgers and Secret Cinema. Redrice Ventures counts Sir Andy Murray and Olympic triathlete Alistair Brownlee amongst its sports-focused backers.
The speed matters here. Most consumer health companies spend years grinding through product development and clinical validation before approaching institutional investors. English, a registered nutritionist with substantial social media reach, appears to have collapsed that timeline entirely.
What Active Partners is buying isn't a pharmaceutical pipeline. The firm's track record spans lifestyle hospitality and experiential retail, not medical products. Billy Fox, investor at Active Partners, positioned the investment around consumer sentiment rather than clinical outcomes, noting that 'today's consumers are more informed and purposeful about their wellbeing than ever before'.
That framing is deliberate. The UK gut health supplement market operates in a regulatory grey zone where probiotic products can make certain claims without requiring the evidence standards expected of medicines. The Advertising Standards Authority has repeatedly challenged supplement marketing in recent years, but enforcement remains patchy across e-commerce channels.
Epetōme's stated intention to 'increase investment into clinical testing across both probiotics and prebiotics' suggests the company recognises this vulnerability. Whether that represents genuine scientific rigour or defensive positioning against future regulatory tightening is harder to parse. Jimmy Hill, Epetōme's co-founder and executive chair, emphasised the funding would enable the brand to 'double down on our investment into science', but offered no specifics on trial design, endpoints, or publication plans.
The involvement of Redrice Ventures adds another dimension. Brownlee's endorsement—'products grounded in science that genuinely make people's lives healthier and better'—carries weight with health-conscious consumers, particularly those in endurance sport circles where gut health has become a performance obsession. But athletic endorsement and clinical validation aren't the same thing, however much the language blurs between them.
The business model beneath the bottle
Strip away the wellness rhetoric and Epetōme represents a proven direct-to-consumer playbook: leverage founder credibility and social reach to acquire customers cheaply, convert them to subscription revenue, then use that traction to raise capital for retail expansion and international markets. It's worked for protein powder brands, vitamin companies, and collagen supplements. The gut microbiome is simply the current iteration.
What makes this funding notable isn't the model—it's the valuation multiple that investors are presumably willing to accept for such early-stage revenue. Consumer supplement brands typically face brutal economics: high customer acquisition costs, low barriers to entry, and retention rates that crater once the initial enthusiasm fades. According to research from McKinsey published last year, fewer than 40 per cent of supplement subscribers remain active after six months.
English's claim to have built 'a highly loyal consumer base' after just twelve months lacks supporting data. Customer acquisition and customer retention are fundamentally different achievements, and the supplement industry has spent decades confusing the two. Loyalty requires proof that consumers repurchase consistently over years, not quarters.
Where the smart money is actually flowing
Active Partners' entry into functional supplements follows a broader pattern amongst consumer-focused VCs. With restaurant and hospitality investments battered by post-pandemic economics, firms have pivoted towards products with higher margins and digital distribution advantages. Supplements tick both boxes, particularly when fronted by founders who can drive organic social traffic.
The question is whether these investors have properly stress-tested the retention model, or whether they're banking on a quick exit to a larger CPG acquirer before the churn data becomes inconvenient. Unilever, Nestlé, and Danone have all made aggressive moves into functional nutrition in recent years, often acquiring brands with modest revenue but strong social presence.
For Epetōme, international expansion presents both opportunity and risk. Probiotic regulations vary significantly across markets—what's permissible to claim in the UK may face challenges from European or US regulators. The company's stated commitment to clinical testing could provide regulatory insulation, assuming those trials are designed to meet standards required in target markets rather than simply generating marketing collateral.
The influencer-to-founder pipeline isn't new, but it's accelerating. English joins a cohort of digital-first entrepreneurs who've translated audience into equity value with remarkable efficiency. Whether that value endures depends on factors venture capitalists historically struggle to model: scientific credibility, long-term product efficacy, and whether consumers ultimately care more about evidence or endorsements. The next eighteen months, as Epetōme pushes into new markets and presumably begins publishing trial data, will indicate which bet Active Partners actually made.
